Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Koreansk studie om säkerhet och effektivitet av oad trippelterapi i typ 2 -diabetes (TRIO)

29 september 2026 uppdaterad av: Chong Kun Dang Pharmaceutical

En multicenter, prospektiv, icke-interventionell observationsstudie för att utvärdera säkerheten och effektiviteten för OAD Triple Therapy hos koreanska typ 2-diabetiska mellituspatienter

A multicenter, prospective, non-interventional observation study to evaluate the safety and effectiveness of OAD triple therapy in Korean Type 2 diabetic mellitus patients.

Studieöversikt

Detaljerad beskrivning

The study was designed as a multicenter, prospective, non-interventional, observational study in patients with type 2 diabetes mellitus who had inadequate glycemic control with conventional combination oral hypoglycemic agents including metformin.

Participants in this study will have type 2 diabetes mellitus with insufficient glycemic control on conventional combination therapy with a DPP-4i or SGLT2i oral hypoglycemic agent, including metformin, requiring the addition of one of the following: SGLT-2i, DPP-4i, or TZD.

The 3-drug combination therapy will be prescribed to subjects based on the medical judgment of the investigator based on the licensure of SGLT-2i, DPP-4i, or TZD(efficacy, dosing, precautions for use, etc.) in a real-world practice setting and all treatment and observation, including administration of medications and laboratory tests, will be based on the medical judgment of the investigator.

Studietyp

Observationell

Inskrivning (Beräknad)

10000

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

  • Namn: Soo Lim, M.D, Ph.D.
  • Telefonnummer: 82-2-6373-0773
  • E-post: limsoo@snu.ac.kr

Studieorter

    • Gyeonggi-do
      • Seongnam-si, Gyeonggi-do, Sydkorea
        • Rekrytering
        • Seoul National University Bundang Hospital
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

19 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Patients with type 2 diabetes mellitus whose glycemic control is inadequate on 2 oral hypoglycemic agents, including metformin.

Beskrivning

Inclusion Criteria:

  1. Patients with type 2 diabetes who are 19 years of age or older at the time of enrollment.
  2. Continued DPP-4i or SGLT-2i oral hypoglycemic combination therapy with metformin for at least 8 weeks prior to enrollment.
  3. 7.0% ≤ HbA1c < 10.0% based on laboratory tests performed within 4 weeks of enrollment.
  4. Voluntarily give written informed consent after being told about the study.

Exclusion Criteria:

  1. Patients with type 1 diabetes and secondary diabetes.
  2. Patients receiving concomitant therapy with 3 or more oral hypoglycemic agents within 8 weeks of enrollment.
  3. Requiring treatment with insulin, GLP-1, etc. in addition to oral hypoglycemic agents during the study.
  4. End-stage renal disease and hemodialysis patients.
  5. diabetic ketoacidosis Patients.
  6. Pregnant and lactating women.
  7. Patients who are contraindicated by any of the "Precautions for Use" in the license for the drug being administered during the study, given the observational nature of the study under routine practice.
  8. Patients with a history of hypersensitivity to the investigational drug or any of its components or excipients.
  9. Anyone else deemed by the investigator to be unsuitable for participation in the study.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiv: PROSPECTIVE

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
Metformin/DPP4i/SGLT2i

Metformin + DPP4i 2-drug combination plus one of the SGLT-2i class of drugs.

SGLT2 inhibitor class of drugs

DPP4 inhibitor class of drugs

Metformin/DPP4i/TZD

Metformin + DPP4i 2-drug combination plus one of the TZD class of drugs.

DPP4 inhibitor class of drugs

Thiazolidinedione class of drugs

Metformin/SGLT2i/DPP4i

Metformin + SGLT2i 2-drug combination plus one of the DPP4i class of drugs.

SGLT2 inhibitor class of drugs

DPP4 inhibitor class of drugs

Metformin/SGLT2i/TZD

Metformin + SGLT2i 2-drug combination plus one of the TZD class of drugs.

SGLT2 inhibitor class of drugs

Thiazolidinedione class of drugs

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Safety Evaluation of Triple Combination Therapy with SGLT-2i, DPP-4i, or TZD Class Drugs, Including Metformin
Tidsram: Up to 24 months

Safety will be assessed based on all adverse events, laboratory test results, and vital signs collected after enrollment during the study period.

Up to 24 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Changes in HbA1c
Tidsram: 3, 6, (9), 12, 18, and 24 months

Evaluation of HbA1c(%) Change Compared to Baseline in Each Combination Group

3, 6, (9), 12, 18, and 24 months
Changes in FPG
Tidsram: 3, 6, (9), 12, 18, and 24 months

Evaluation of FPG(mg/dL) Change Compared to Baseline in Each Combination Group

3, 6, (9), 12, 18, and 24 months
Percentage of Subjects with HbA1c < 7.0%
Tidsram: 3, 6, (9), 12, 18, and 24 months

Percentage of Subjects with HbA1c < 7.0% in Each Combination Group

3, 6, (9), 12, 18, and 24 months
Percentage of Subjects with HbA1c < 6.5%
Tidsram: 3, 6, (9), 12, 18, and 24 months

Percentage of Subjects with HbA1c < 6.5% in Each Combination Group

3, 6, (9), 12, 18, and 24 months
Factors influencing HbA1c change at each time point in each combination group.
Tidsram: 3, 6, (9), 12, 18, and 24 months

demographics, previous hypoglycemic medications, hypoglycemic medication components and doses, duration of hypoglycemic medication, duration of disease, comorbidities, concomitant medications, etc.

3, 6, (9), 12, 18, and 24 months

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Changes in Weight
Tidsram: 3, 6, (9), 12, 18, 24 months

Changes in Weight(kg) Compared to Baseline in Each Combination Group

3, 6, (9), 12, 18, 24 months
Changes in waist circumference
Tidsram: 12 and 24 months

Changes in waist circumference(cm) compared to Baseline in Each Combination Group

12 and 24 months
Changes in body composition(protein mass)
Tidsram: 12 and 24 months

Change in total protein mass from baseline in each combination group, as measured using InBody 770 or a higher model.

12 and 24 months
Changes in body composition(protein mass)
Tidsram: 12 and 24 months

Change in protein mass from baseline in each combination group, as measured using InBody 770 or a higher model.

12 and 24 months
Changes in body composition(body fat)
Tidsram: 12 and 24 months

Change in body fat mass from baseline in each combination group, as measured using InBody 770 or a higher model.

12 and 24 months
Changes in body composition(mineral mass)
Tidsram: 12 and 24 months

Change in mineral mass from baseline in each combination group, as measured using InBody 770 or a higher model.

12 and 24 months
Changes in Fatty Liver Index
Tidsram: 6, 12, 18, and 24 months

Changes in Fatty Liver Index compared to Baseline in Each Combination Group

6, 12, 18, and 24 months
Changes in AST
Tidsram: 6, 12, 18, and 24 months

Changes in AST(IU/L) Compared to Baseline in Each Combination Group

6, 12, 18, and 24 months
Changes in ALT
Tidsram: 6, 12, 18, and 24 months

Changes in ALT(IU/L) Compared to Baseline in Each Combination Group

6, 12, 18, and 24 months
Changes Platelet Levels
Tidsram: 6, 12, 18, and 24 months

Changes in Platelet(10^3/uL) Levels Compared to Baseline in Each Combination Group

6, 12, 18, and 24 months
Changes in Blood Lipid Levels(Total cholesterol, LDL-C, HDL-C, TG)
Tidsram: 6, 12, 18, and 24 months

Change in Total cholesterol, LDL-C, HDL-C, TG(mg/dL) compared to Baseline in Each Combination Group

6, 12, 18, and 24 months
Changes in Insulin-Related Test Levels(HOMA-IR)
Tidsram: 12 and 24 months

Changes in HOMA-IR compared to Baseline in Each Combination Group

12 and 24 months
Changes in Insulin-Related Test Levels(HOMA-β)
Tidsram: 12 and 24 months

Changes in HOMA-β(%) compared to Baseline in Each Combination Group

12 and 24 months
Changes in eGFR
Tidsram: 6, 12, 18, and 24 months

Changes in eGFR(mL/min/1.73m2) compared to Baseline in Each Combination Group

6, 12, 18, and 24 months
Changes in UACR
Tidsram: 6, 12, 18, and 24 months

Changes in UACR(mg/g) compared to Baseline in Each Combination Group

6, 12, 18, and 24 months
Change in hsCRP
Tidsram: 12 and 24 months

Change in hsCRP(mg/dL) compared to Baseline in Each Combination Group

12 and 24 months
Change in ProBNP(or NT-ProBNP)
Tidsram: 12 and 24 months

Change in ProBNP(or NT-ProBNP)(pg/mL) compared to Baseline in Each Combination Group

12 and 24 months
Change in PP2 Compared to Baseline in Each Combination Group
Tidsram: 3, 6, (9), 12, 18, and 24 months

Change in PP2(mg/dL) compared to Baseline in Each Combination Group.

3, 6, (9), 12, 18, and 24 months
Incidence Rate of Major Adverse Cardiovascular Events(MACE)
Tidsram: 24 month

Incidence Rate of Major Adverse Cardiovascular Events(MACE) from Baseline to 24 Months for Each Combination Group

24 month
Incidence Rate of Diabetic Microvascular Events
Tidsram: 24 month

Incidence Rate of Diabetic Microvascular Events from Baseline to 24 Months for Each Combination Group

24 month

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

2 januari 2024

Primärt slutförande (Beräknad)

1 oktober 2028

Avslutad studie (Beräknad)

31 december 2029

Studieregistreringsdatum

Först inskickad

30 juni 2024

Först inskickad som uppfyllde QC-kriterierna

18 februari 2025

Första postat (Faktisk)

20 februari 2025

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

30 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

29 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera